Guggenheim Capital’s iShares Biotechnology ETF IBB Stock Holding History

Guggenheim Capital’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q3	–	Sell	-36,678	Closed	-$2.13M	–	3111
2013 Q2	$2.13M	Buy	+36,678	New	+$2.12M	0.01%	1492

Other funds holding IBB

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Guggenheim Capital's IBB Position: Q3 2013 in Review

Guggenheim Capital sold out of iShares Biotechnology ETF (IBB) in Q3 2013, closing a stake of 36,678 shares — an estimated $2.13M sold.

Guggenheim Capital first reported a position in IBB in Q2 2013 and held it in 1 quarter. The position peaked at $2.13M in Q2 2013. 253 funds tracked by Wall St. Rank hold IBB as of Q3 2013.

Guggenheim Capital reported no remaining iShares Biotechnology ETF position as of Q3 2013 after selling out during the quarter.
Guggenheim Capital sold 36,678 iShares Biotechnology ETF shares in Q3 2013, an estimated $2.13M.
Guggenheim Capital first reported a position in iShares Biotechnology ETF in Q2 2013 and held it in 1 quarter.
Guggenheim Capital's iShares Biotechnology ETF position peaked at $2.13M in Q2 2013.
253 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2013.

Based on Guggenheim Capital's 13F filing for Q3 2013, filed 14 Nov 2013.